Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Losing interest in activities that were once enjoyable
The injection meaningfully improved sleep apnea symptoms in those with moderate-to-severe OSA and obesity with and without positive airway pressure (PAP) therapy in the SURMOUNT-OSA trials
References Younossi, Z
Cardiometabolic Markers Secondary endpoints in published trials have included blood pressure, lipid panel, and inflammatory markers, giving researchers additional data points for modeling broader cardiometabolic effects of triple agonism
The trial reported that no apparent signal of increased major adverse cardiovascular events (MACE) a composite endpoint typically comprising cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke was observed compared to placebo
US$ 21.92
US$ 29.96
US$ 29.73
US$ 23.96
US$ 28.08
US$ 23.80
US$ 29.95
US$ 28.81
